These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24809242)

  • 1. Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms.
    Edgar CJ; Blaettler T; Bugarski-Kirola D; Le Scouiller S; Garibaldi GM; Marder SR
    Psychiatry Res; 2014 Aug; 218(1-2):219-24. PubMed ID: 24809242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia.
    Patrick DL; Burns T; Morosini P; Rothman M; Gagnon DD; Wild D; Adriaenssen I
    Curr Med Res Opin; 2009 Feb; 25(2):325-38. PubMed ID: 19192977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.
    Bugarski-Kirola D; Iwata N; Sameljak S; Reid C; Blaettler T; Millar L; Marques TR; Garibaldi G; Kapur S
    Lancet Psychiatry; 2016 Dec; 3(12):1115-1128. PubMed ID: 27816567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia.
    Hirayasu Y; Sato S; Takahashi H; Iida S; Shuto N; Yoshida S; Funatogawa T; Yamada T; Higuchi T
    BMC Psychiatry; 2016 Mar; 16():66. PubMed ID: 26980460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study.
    Olié JP; Spina E; Murray S; Yang R
    Int Clin Psychopharmacol; 2006 May; 21(3):143-51. PubMed ID: 16528136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies.
    Bugarski-Kirola D; Blaettler T; Arango C; Fleischhacker WW; Garibaldi G; Wang A; Dixon M; Bressan RA; Nasrallah H; Lawrie S; Napieralski J; Ochi-Lohmann T; Reid C; Marder SR
    Biol Psychiatry; 2017 Jul; 82(1):8-16. PubMed ID: 28117049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia.
    Leucht S; Barabássy Á; Laszlovszky I; Szatmári B; Acsai K; Szalai E; Harsányi J; Earley W; Németh G
    Neuropsychopharmacology; 2019 Aug; 44(9):1589-1596. PubMed ID: 30836381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J; Arango C; Garcia-Garcia M; Rejas J;
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies.
    Marder S; Fleischhacker WW; Earley W; Lu K; Zhong Y; Németh G; Laszlovszky I; Szalai E; Durgam S
    Eur Neuropsychopharmacol; 2019 Jan; 29(1):127-136. PubMed ID: 30470662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors.
    Fleischhacker W; Galderisi S; Laszlovszky I; Szatmári B; Barabássy Á; Acsai K; Szalai E; Harsányi J; Earley W; Patel M; Németh G
    Eur Psychiatry; 2019 May; 58():1-9. PubMed ID: 30738380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related quality of life in patients with prominent negative symptoms: results from a multicenter randomized Phase II trial on bitopertin.
    Rofail D; Regnault A; le Scouiller S; Berardo CG; Umbricht D; Fitzpatrick R
    Qual Life Res; 2016 Jan; 25(1):201-11. PubMed ID: 26143058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia.
    Dunayevich E; Buchanan RW; Chen CY; Yang J; Nilsen J; Dietrich JM; Sun H; Marder S
    Schizophr Res; 2017 Apr; 182():90-97. PubMed ID: 27789188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
    Umbricht D; Alberati D; Martin-Facklam M; Borroni E; Youssef EA; Ostland M; Wallace TL; Knoflach F; Dorflinger E; Wettstein JG; Bausch A; Garibaldi G; Santarelli L
    JAMA Psychiatry; 2014 Jun; 71(6):637-46. PubMed ID: 24696094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study.
    Bugarski-Kirola D; Wang A; Abi-Saab D; Blättler T
    Eur Neuropsychopharmacol; 2014 Jul; 24(7):1024-36. PubMed ID: 24735806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia.
    Nasrallah H; Morosini P; Gagnon DD
    Psychiatry Res; 2008 Nov; 161(2):213-24. PubMed ID: 18848731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
    Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms.
    Stauffer VL; Song G; Kinon BJ; Ascher-Svanum H; Chen L; Feldman PD; Conley RR
    Schizophr Res; 2012 Feb; 134(2-3):195-201. PubMed ID: 22019076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies.
    O'Gorman C; Kapur S; Kolluri S; Kane J
    Hum Psychopharmacol; 2011; 26(4-5):282-90. PubMed ID: 21638329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
    Davidson M; Saoud J; Staner C; Noel N; Luthringer E; Werner S; Reilly J; Schaffhauser JY; Rabinowitz J; Weiser M; Luthringer R
    Am J Psychiatry; 2017 Dec; 174(12):1195-1202. PubMed ID: 28750582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.